Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Ovarian Cancer Recurrent 1

Interventions

Bevacizumab 21Paclitaxel 19Carboplatin 15pembrolizumab 14Specimen Handling 14liposomal doxorubicin 12Magnetic Resonance Spectroscopy 12Cyclophosphamide 11olaparib 10Gemcitabine 10fludarabine 9Topotecan 8Biopsy 8Fulvestrant 7niraparib 6Nivolumab 6palbociclib 5Taxes 5Immunoglobulin G 5Doxorubicin 5Disulfides 5aldesleukin 4trastuzumab deruxtecan 3mirvetuximab soravtansine 3binimetinib 3Oxaliplatin 3Cisplatin 3AZD5305 31-dodecylpyridoxal 3ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × 1-dodecylpyridoxal × 30 days × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡